{
    "ticker": "HCM",
    "name": "Hutchison China MediTech Limited",
    "description": "Hutchison China MediTech Limited (HCM) is a leading biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases. Founded in 1999, HCM operates through its two main segments: pharmaceuticals and consumer health. The company has a robust pipeline of drug candidates, particularly in oncology, with several products in various stages of clinical trials. HCM's commitment to research and development is evident through its collaboration with various international partners, aiming to accelerate the development of novel therapeutics. One of its flagship products, Savolitinib, targets non-small cell lung cancer, while other promising candidates are in development for additional malignancies. HCM is also dedicated to expanding its reach in the global market, seeking to leverage its strong foundation in Asia to bring innovative treatments to patients worldwide. The company\u2019s mission revolves around improving patient outcomes and advancing healthcare through groundbreaking science and technology.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Hong Kong",
    "founded": "1999",
    "website": "https://www.hutch-med.com",
    "ceo": "Simon To",
    "social_media": {
        "twitter": "https://twitter.com/HutchMed",
        "linkedin": "https://www.linkedin.com/company/hutchison-china-medic-tech-limited/"
    },
    "investor_relations": "https://www.hutch-med.com/investors",
    "key_executives": [
        {
            "name": "Simon To",
            "position": "CEO"
        },
        {
            "name": "David H. B. D. T. Yip",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Savolitinib",
                "Fruquintinib"
            ]
        },
        {
            "category": "Consumer Health",
            "products": [
                "Over-the-counter products"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hutchison China MediTech Limited | Biopharmaceuticals and Innovative Medicines",
        "meta_description": "Explore Hutchison China MediTech Limited, a leading biopharmaceutical company in China, dedicated to developing innovative medicines for cancer and autoimmune diseases.",
        "keywords": [
            "HCM",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Innovative Medicines",
            "Savolitinib"
        ]
    },
    "faq": [
        {
            "question": "What does HCM focus on?",
            "answer": "HCM focuses on discovering and developing innovative medicines for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of HCM?",
            "answer": "Simon To is the CEO of Hutchison China MediTech Limited."
        },
        {
            "question": "Where is HCM headquartered?",
            "answer": "HCM is headquartered in Hong Kong."
        },
        {
            "question": "What are some of HCM's products?",
            "answer": "Some of HCM's products include Savolitinib and Fruquintinib."
        },
        {
            "question": "When was HCM founded?",
            "answer": "HCM was founded in 1999."
        }
    ],
    "competitors": [
        "BMY",
        "MRK",
        "JNJ",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}